Key result
Structural modifications of doxorubicin altered topoisomerase II interaction and apoptosis in human melanoma cells, though stabilization of cleavable complexes did not strictly correlate with cytotoxicity.
Population
Parental human ME18 melanoma cells and the ME18/R subline resistant to doxorubicin (DOX)
Design
Preclinical
Authors
Loading...
Should not change doxorubicin use in melanoma; hypothesis-generating for analog optimization in topoisomerase II targeting.
Structural modifications of doxorubicin influence topoisomerase II interaction and apoptosis in melanoma cells, but the biological response varies by cell type.
Gruber et al. (2007) studied Human melanoma. Doxorubicin analogs (Annamycin and WP903) vs. Doxorubicin was evaluated on Cytotoxicity (IC50) and apoptosis. Structural modifications of doxorubicin altered topoisomerase II interaction and apoptosis in human melanoma cells, though stabilization of cleavable complexes did not strictly correlate with cytotoxicity.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: